Harmony Biosciences Holdings, Inc. (HRMY) Stock Price & Analysis
Harmony Biosciences Holdings, Inc. (HRMY) rose 5.28% to USD 34.1 as of June 10, 2026 at 03:48 UTC, according to Nexqual real-time market data.
HRMY last closed at USD 32.39; the session ranged USD 32.73–34.2 on volume of 1,059,365 shares. Market capitalization is $1.97B, with a 52-week range of USD 25.52–40.87 (NGM). Source: Nexqual, June 10, 2026 at 03:48 UTC.
Key Statistics (as of June 10, 2026 at 03:48 UTC)
| Price | USD 34.1 |
|---|---|
| Change | ▲ 5.28% (up) |
| Previous Close | USD 32.39 |
| Open | USD 32.76 |
| Day Range | USD 32.73 – 34.2 |
| 52-Week Range | USD 25.52 – 40.87 |
| Volume | 1,059,365 shares |
| Market Cap | $1.97B |
| Exchange | NGM |
Technical Analysis (HRMY)
Nexqual's technical model rates HRMY "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 03:48 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.46 (neutral) |
| vs SMA50 | Above (USD 30.54) |
| MACD | 0.62 (positive) |
Analyst Ratings (HRMY)
Wall Street analysts rate HRMY "None" based on 11 analysts, with a mean price target of USD 44.36 (range USD 28–85), per Nexqual as of June 10, 2026 at 03:48 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 44.36 |
| High Target | USD 85 |
| Low Target | USD 28 |
| Buy / Hold / Sell | 6 / 4 / 1 |
Earnings (HRMY)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 1.1 |
| Revenue Estimate | $244.55M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.79 vs est 0.93 ▼ miss |
| 2025-12-31 | USD 0.57 vs est 1.07 ▼ miss |
| 2025-09-30 | USD 1.08 vs est 0.86 ▲ beat |
| 2025-06-30 | USD 0.92 vs est 0.96 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Financials & Fundamentals (HRMY)
| Total Revenue | $899.11M |
|---|---|
| Revenue Growth (YoY) | +16.60% |
| Gross Margin | +76.55% |
| Operating Margin | +17.31% |
| Profit Margin | +16.20% |
| ROE | +17.86% |
| Debt / Equity | 18.08 |
| Current Ratio | 3.58 |
| Total Cash | $640.92M |
| Total Debt | $164.61M |
| Free Cash Flow | $149.73M |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Financial Health Score (HRMY)
Nexqual rates Harmony Biosciences Holdings, Inc.'s overall financial health "Strong" across five dimensions, as of June 10, 2026 at 03:48 UTC.
| Growth | Strong — Revenue +22% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 77%, operating 17% |
| Balance Sheet | Strong — $641M cash vs $165M debt, net cash position |
| Cash Flow | Strong — FCF $150M, 17% margin |
| Efficiency | Solid — ROE 18%, ROA 10.2% |
Ownership (HRMY)
| Insider Ownership | +11.69% |
|---|---|
| Institutional Ownership | +103.38% |
| Shares Outstanding | 57.89M |
| Float | 51.73M |
| Short % of Float | +13.73% |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Leadership (HRMY)
Harmony Biosciences Holdings, Inc. is led by Jeffrey M. Dayno (age 68), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:48 UTC.
| President, CEO & Director | Jeffrey M. Dayno (age 68) |
|---|---|
| Founder & Non-Executive Chairman | Jeffrey S. Aronin (age 57) |
| Chief Operating Officer | Peter Anastasiou (age 55) |
| Executive VP & Chief Strategy Officer | Andrew Serafin (age 50) |
| Chief Financial Officer | Glenn M. Reicin (age 60) |
Major Backers & Investors (HRMY)
Notable institutional backers of Harmony Biosciences Holdings, Inc. include American Century Companies Inc, FMR, LLC, LSV Asset Management, according to Nexqual as of June 10, 2026 at 03:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| American Century Companies Inc | 6.96% |
| FMR, LLC | 5.45% |
| LSV Asset Management | 3.5% |
| SG Americas Securities, LLC | 3.49% |
| Armistice Capital, LLC | 2.81% |
| Fidelity | 2.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 18.17% |
| Vanguard Group | 14.85% |
| State Street | 3.71% |
| Dimensional Fund Advisors | 3.59% |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
From Harmony Biosciences Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- There are multiple FDA approved therapies for the treatment of DS, LGS or both DS and LGS including, but not limited to, products from Jazz Pharmaceuticals for the treatment of DS and LGS, UCB for the treatment 10 Table of Contents of DS and LGS, Biocodex for the treatment of DS, Eisai Co., Ltd. for the treatment of LGS, Janssen for the treatment of LGS, GlaxoSmithKline for the treatment of LGS, and Assertio Holdings for the treatment of LGS.
- Any patent that issues from these applications is expected to expire in May 2044, not including any possible adjustment to patent term.   Our HBS-102 patent portfolio comprises three patent families.
- For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and our issued patents may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates.
- Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights.
Partnerships
- In July 2022, we entered into a License and Commercialization Agreement with Bioprojet (the "2022 LCA") whereby we obtained exclusive rights to manufacture, develop and commercialize one or more next generation pitolisant based products in the United States and Latin America.
- Next Gen Pitolisant Formulations: Pitolisant Gastro-Resistant and Pitolisant High-Dose In July 2022, we entered into the 2022 LCA with Bioprojet whereby we obtained exclusive rights to manufacture, develop and commercialize one or more new products based on pitolisant in the United States and Latin America, with the potential to add additional indications and formulations upon the agreement of both parties (see "Strategic Agreements" below).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | USD 76.91 | ▲ 3.75% |
| INBX | Inhibrx Biosciences, Inc. | USD 89.1 | ▲ 2.4% |
| KROS | Keros Therapeutics, Inc. | USD 10.07 | ▼ 2.23% |
| PCVX | Vaxcyte, Inc. | USD 46.88 | ▼ 1.01% |
| RLAY | Relay Therapeutics, Inc. | USD 14.09 | ▲ 4.22% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:48 UTC. This page is informational and not investment advice.